Cancer Research UK and Vaccitech Oncology Limited (VOLT), today (Wednesday) announce a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lung cancer.
The vaccine treatment developed by VOLT, a strategic collaboration between Vaccitech Ltd and the Ludwig Institute for Cancer Research, is designed to stimulate the body's immune system to attack cancer cells. It will deliver cancer-associated antigens (MAGE A3 and NY-ESO-1) to antigen presenting cells called dendritic cells, causing the immune system to produce cytotoxic T cells, which target and kill cancerous cells expressing the antigens.
abit nervous 😕
Relvar/trelegy 
Hello from Chom 🐕
Easyhaler Salbutamol Sulfate inhaler
Primrose 123
